EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Advances in Anaplastic Thyroid Cancer Treatment

Sarah Hamidi, Anastasios Maniakas, Maria E Cabanillas

Endocrinology and Metabolism Clinics of North America · 2025-09 · 54 (3) · 361-375

DOI: 10.1016/j.ecl.2025.03.009 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrinology and Metabolism Clinics of North America, 2025-09. Verfasst von Sarah Hamidi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, 1515 Holcombe Boulevard, Unit 1461, Houston, TX…. Hauptthemen laut MEDLINE: Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Merck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In 2025, it is no longer appropriate to view anaplastic thyroid cancer (ATC) patients with the sense of nihilism and hopelessness characteristic of the approach used in past decades. Early, rapid somatic genomic testing to determine BRAF (v-raf murine sarcoma viral oncogene homolog B1) status is critical for the optimal management of ATC. Surgical resection of the primary tumor after neoadjuvant approach, regardless of stage, should be the goal in most patients with BRAFV600E-mutated ATC to decrease locoregional complications, improve quality of life, and prolong survival. Combination therapy with kinase inhibitors plus immune checkpoint inhibitors is the preferred treatment regimen in patients with metastatic ATC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid Carcinoma, AnaplasticThyroid NeoplasmsHumansProto-Oncogene Proteins B-rafProtein Kinase Inhibitors

Stichwörter der Autor:innen

BRAFV600EImmunotherapyKinase inhibitorsMultimodal therapySystemic therapyUndifferentiated

Substanzen

Proto-Oncogene Proteins B-rafProtein Kinase InhibitorsBRAF protein, human

Autor:innen und Institutionen

  • Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, 1515 Holcombe Boulevard, Unit 1461, Houston, TX 77030, USA.
  • Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer, 1515 Holcombe Boulevard, Unit 1445, Houston, TX 77030, USA.
  • Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, 1515 Holcombe Boulevard, Unit 1461, Houston, TX 77030, USA. Electronic address: mcabani@mdanderson.org.

Förderung

  • Merck

Zitieren

APA

Hamidi, S., Maniakas, A., & Cabanillas, M. E. (2025). Advances in Anaplastic Thyroid Cancer Treatment. Endocrinology and Metabolism Clinics of North America, 54(3), 361-375. https://doi.org/10.1016/j.ecl.2025.03.009

Vancouver

Hamidi S, Maniakas A, Cabanillas ME. Advances in Anaplastic Thyroid Cancer Treatment. Endocrinology and Metabolism Clinics of North America. 2025;54(3):361-375. doi:10.1016/j.ecl.2025.03.009

BibTeX
@article{Hamidi2025,
  author = {Hamidi, Sarah and Maniakas, Anastasios and Cabanillas, Maria E},
  title = {Advances in Anaplastic Thyroid Cancer Treatment},
  journal = {Endocrinology and Metabolism Clinics of North America},
  year = {2025},
  volume = {54},
  number = {3},
  pages = {361--375},
  doi = {10.1016/j.ecl.2025.03.009}
}
Kostenlos starten →